BioCentury
ARTICLE | Clinical News

Pfizer's tanezumab meets in Phase III for OA pain

July 18, 2018 9:41 PM UTC

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) said tanezumab met the three co-primary endpoints compared with placebo in the Phase III A4091056 trial to treat osteoarthritis pain. Pfizer said the data support the use of the humanized mAb against nerve growth factor (NGF) as a non-opioid treatment option in the indication, and the company hopes to submit an NDA to FDA in 2019.

The trial's primary endpoints evaluated the change from baseline to week 16 in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score, WOMAC physical function score and Patient's Global Assessment (PGA) of OA. Pfizer did not disclose detailed efficacy data...

BCIQ Company Profiles

Eli Lilly and Co.

Pfizer Inc.

BCIQ Target Profiles

Nerve growth factor (NGF)